Aro Biotherapeutics Company
Latest round
- Series B
Last raised
- Dec 2022
Total raised
- $66M
Investors
- 8
About Aro Biotherapeutics Company
Founded in 2018 in Philadelphia, US, Aro Biotherapeutics Company develops tissue-targeted genetic medicines.Aro Biotherapeutics specializes in the development of tissue-targeted genetic medicines through its proprietary Centyrin technology. The company’s primary offerings include a pipeline of Centyrin-RNA drug conjugates aimed at precisely modulating gene targets associated with various diseases, particularly those previously deemed difficult to treat. These products utilize receptor-specific Centyrins conjugated with oligonucleotides, ensuring targeted delivery of therapeutic agents to disease tissues. Aro's focus extends to addressing conditions such as Late-Onset Pompe Disease (LOPD), with ongoing clinical trials evaluating the efficacy of their therapeutic candidates. The company's business transactions are structured around collaborations with industry partners, which may include revenue-sharing agreements or milestone payments linked to the progress of their clinical programs. Additionally, the firm engages in B2B transactions, focusing on securing contracts with healthcare organizations and research institutions for the development and commercialization of its Centyrin-based therapeutics. Aro is focused on launching new products and expanding into international markets. Specific target regions for expansion will be announced as the company progresses with its clinical trials and product development.
Who invested in Aro Biotherapeutics Company
8 investors across 2 rounds
See all investors in Aro Biotherapeutics Company
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Aro Biotherapeutics Company
Who invested in Aro Biotherapeutics Company?
Aro Biotherapeutics Company has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aro Biotherapeutics Company raised?
Aro Biotherapeutics Company has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Aro Biotherapeutics Company last raise money?
Aro Biotherapeutics Company's most recent round on record is a Series B, in Dec 2022.
What does Aro Biotherapeutics Company do?
Founded in 2018 in Philadelphia, US, Aro Biotherapeutics Company develops tissue-targeted genetic medicines.
Where is Aro Biotherapeutics Company headquartered?
Aro Biotherapeutics Company is headquartered in Philadelphia, US.
Which VCs invest in companies like Aro Biotherapeutics Company?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Aro Biotherapeutics Company's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Aro Biotherapeutics Company? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.